Moderna reports positive Phase 3 melanoma trial for mRNA cancer therapy

AI summary

Moderna and Merck announced positive topline Phase 3 results for intismeran autogene, an individualized mRNA neoantigen therapy used with KEYTRUDA in patients with completely resected stage IIB-IV melanoma. The trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, marking the first positive Phase 3 result for an individualized neoantigen therapy and an mRNA-based cancer therapy.